Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia

Maja Stosic 1,*,†, Marija Milic 1,2,†, Milos Markovic 3, Ivan Karlic 1, Zoran Bukumiric 4, Marko Veljkovic 1, Darija Kisic Tepavcevic 5, Vlajdan Saponjic 1, Dragana Plavsa 1, Sofija Jovanovic 6 and Verica Jovanovic 1,*

1 Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”, Belgrade, Dr Subotica 5, 11000 Belgrade, Serbia; marija_milic@batut.org.rs (M.M.); ivana_kelic@batut.org.rs (I.K.); marko_veljkovic@batut.org.rs (M.V.); vladan_saponjic@batut.org.rs (V.S.); dragana_djordjevic@batut.org.rs (D.P.)
2 Department of Epidemiology, Faculty of Medicine, University of Pristina Temporarily Seated in Kosovska Mitrovica, 38220 Kosovska Mitrovica, Serbia
3 Faculty of Medicine, Institute for Microbiology and Immunology, University of Belgrade, Dr Subotica 1, 11000 Belgrade, Serbia; milos.markovic@med.bg.ac.rs
4 Faculty of Medicine, Institute for Medical Statistics and Informatics, University of Belgrade, Dr Subotica 9, 11000 Belgrade, Serbia; zoran.bukumiric@med.bg.ac.rs
5 Faculty of Medicine, Institute of Epidemiology, University of Belgrade, Visegradska 26A, 11000 Belgrade, Serbia; darijakt@gmail.com
6 Faculty of Medicine, University of Belgrade, Dr Subotica 9, 11000 Belgrade, Serbia; jovanovicdsofija@gmail.com
* Correspondence: maja_stosic@batut.org.rs (M.S.); verica_jovanovic@batut.org.rs (V.J.); Tel.: +381-11-2685-476 (M.S. & V.J.)
† These authors contributed equally to this work.

Abstract: The Republic of Serbia applied the booster dose of the following COVID-19 vaccines: BNT162b2 mRNA (Pfizer-BioNTech), Sinopharm BBIBP-CorV (Vero Cell®), Gam-COVID-Vac (Sputnik V) and ChAdOx1 nCoV-19 (AstraZeneca). We aimed to examine the immunogenicity and reactogenicity of the booster dose and identify factors related to immune response and adverse events. Panel study, conducted during August and September 2021, included 300 persons receiving the booster dose at the Institute of Public Health of Serbia. Blood samples were taken on the day of receiving the booster dose, and after 7 and 28 days. When applying homologous regimen, the average increase in anti-spike immunoglobulin G was 8782.2 (after 7 days), 1213.9 after 28 days, while 9179.5 (after 7 days) and 16,728.1 after 28 days of heterologous regimen. Sinopharm BBIBP-CorV (p < 0.001) and Sputnik V (p < 0.001), age 65 and over (p = 0.001) and currently smoking (p < 0.001) were independently associated with lower levels of anti-spike immunoglobulin G. Female sex (OR = 1.77; 95%CI = 1.01–3.12), previous COVID-19 infection (OR = 3.62; 95%CI = 1.13–11.63) and adverse events after the second dose (OR = 2.66; 95%CI = 1.33–5.32) were independently associated with intense systemic adverse events 7 days after. Booster dose significantly increased antibodies titers, especially 28 days after heterologous regimen, without a significant increase in reactogenicity.

Keywords: COVID-19; Serbia; vaccination; booster dose; mix and match strategies; immunogenicity; reactogenicity

1. Introduction

The implementation of COVID-19 vaccines has become the main weapon in the battle of slowing down the coronavirus disease pandemic and reducing morbidity and mortality worldwide [1,2]. Israel was the first country to record a significant decrease in COVID-19 cases in early 2021 due to the mass immunization, but also the first country to question the immunization achievements due to breakthrough infections among fully vaccinated people.
Two main reasons for breakthrough infection occurrence are the emergence of new SARS-CoV-2 variants that escape immunity and waning immunity of the vaccines over time [1,6–8].

Policymakers of many countries decided to administer a booster dose of COVID-19 vaccines and apply mix and match strategies based on the following reasons: lower efficacy of certain vaccines, waning immunity and the increase in new COVID-19 cases from June 2021 [1,9–13]. The Republic of Serbia was among the first countries to start applying the booster dose of COVID-19 vaccines, allowing fully vaccinated individuals to receive any of the four COVID-19 vaccines available in the country: BNT162b2 mRNA (Pfizer-BioNTech), Sinopharm BBIBP-CorV (Vero Cell®), Gam-COVID-Vac (Sputnik V) and ChAdOx1 nCoV-19 (AstraZeneca), six months after receiving the second dose (mix and match strategies) [14].

The results of the first studies on the immunogenicity and reactogenicity of the booster dose are encouraging, showing high immunogenicity of the homologous or heterologous application regimen of all tested vaccines, with good tolerability [15–18]. Additionally, greater effectiveness and safety profile of the COVID-19 vaccine is associated with a greater acceptance of vaccination, especially among men, younger age groups, those with high vaccine hesitance and with lower incomes [19–21].

A recent study from Israel showed that the effectiveness of the booster dose of the BNT162b2 mRNA (Pfizer-BioNTech) vaccine after 7 days was 93% for hospital admission, 92% for severe illness and 81% for death from COVID-19 compared to receiving only two doses of the same vaccine 5 months ago [22]. Most of the current studies examined the immune response, reactogenicity and effectiveness of BNT162b2 mRNA (Pfizer-BioNTech), mRNA-1273 (Moderna) or ChAdOx1 nCoV-19 (AstraZeneca) given as a booster dose within a homologous or heterologous regimens [16–18]. However, there are only a few studies comparing the safety and immunogenicity of the combined application of vaccines approved by the European Medicines Agency with BBIBP-CorV (Sinopharm) or Gam-COVID-Vac (Sputnik V) vaccines [15,18]. Therefore, the aim of this study was to examine immunogenicity and reactogenicity after the application of different COVID-19 vaccines as a booster dose within the mix and match strategies, as well as to identify factors related to immune response and adverse events following vaccination.

2. Materials and Methods

2.1. Study Design

We performed a panel study from 23 August to 20 September 2021 at the Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”. The study was composed of a prospective cohort and three cross-sectional studies. The first cross-sectional study was conducted at the beginning of the study (before receiving a booster dose), the second was conducted seven days later, while the third cross-sectional study was performed on the 28th day after receiving a booster dose of the selected vaccine against COVID-19.

2.2. Sample and Procedure

The sample size was calculated using the program G-power 3.1.6 [23] to detect the effect size of 0.33 in the analysis of variance of repeated measurements. Assuming patient loss during the study duration, or exit from the study of 20%, the final minimum sample size was 159 subjects. The magnitude of the effect was obtained based on the assumed ratios of the values of the explained and residual variance from 0.1 to 0.9. All individuals who applied for a booster dose vaccination at the Institute of Public Health of Serbia “Dr Milan Jovanovic Batut” were consecutively included in the study until the sample size was achieved. The study included 300 consecutive respondents who agreed to participate in the study. The inclusion lasted for 5 days. Only 7 respondents (respond rate 97.7%) refused to participate in the study. There were no vaccination appointments. Coming to the vaccination was voluntary and accidental. We avoided selection bias by the enrollment of consecutive respondents.
Individuals with mental inability to understand the goals and study procedure were excluded as well as the ones having temporary or permanent contraindication for vaccination determined by a medical doctor in accordance with the National Methodological Guidelines for COVID-19 vaccination [24].

Citizens of the Republic of Serbia had the possibility to choose four vaccines offered for primary vaccination: BNT162b2 mRNA (Pfizer-BioNTech), Sinopharm BBIBP-CorV (Vero Cell®), Gam-COVID-Vac (Sputnik V) and ChAdOx1 nCoV-19 (AstraZeneca). All vaccines were administered in a homologous two-dose regimen with an interval of three weeks between two doses except for ChAdOx1 nCoV-19 when the interval between two doses was 12 weeks. From August 2021, all citizens of the Republic of Serbia over the age of 18 could receive the booster dose. The minimum interval from the second dose of the primary vaccination series to the booster dose was 6 months. In addition, all citizens could decide to receive any of the four available vaccines in the Republic of Serbia as a booster dose, regardless of the type of vaccine they had received during the primary vaccination. Depending on whether the participants of our study chose the same or a different type of booster dose of vaccine in relation to the primary vaccination, they were classified in the group with homologous regimens of vaccine administration, or in the group with heterologous regimens.

2.3. Measurements

We conducted an in-person survey facilitated by health workers who were trained on survey administration prior to study initiation. The collection of epidemiological data was carried out at the beginning of the study (before booster dose administration) using a structured questionnaire consisting of closed-ended questions, covering the following topics: socio-demographic characteristics of the respondents, habits and behaviors, concomitant diseases and previous COVID-19, immunosuppressive treatment, allergy to food and drugs, the type of vaccine received as the primary series of COVID-19 vaccination and adverse events after the primary series of COVID-19 vaccination.

2.4. Sample Collection and Measurement of Immunogenicity

Blood samples were collected from the participants in order to determine titers of anti-spike immunoglobulin G (anti-S-IgG) measured by immunoassay on three occasions (before booster doses, 7 and 28 days after the booster dose). Sample analysis was performed in the microbiology laboratory of the Institute of Public Health of Serbia. Antigen-specific humoral immune response was analyzed using Abbott Architect SARS-CoV-2 IgG Chemiluminescent microparticle immunoassay (CMIA), (Abbott Diagnostics, Chicago, IL, USA), performed on the Abbott Architect i2000SR platform. The IgG value was expressed in arbitrary units per mL of serum (AU/mL). According to the manufacturer’s instructions, IgG values equal and above 50 AU/mL were considered positive.

2.5. Reactogenicity of Booster Dose

Reactogenicity data were collected on days 7 and 28 after the COVID-19 booster vaccination by interviewing the participants using the questionnaire related to local and systemic adverse events. Local adverse events were pain, redness, swelling and induration at the application site, while systemic adverse events corresponded to fewer, shivering, fatigue, headache, myalgia and arthralgia [25].

All participants signed a voluntary informed consent form, providing demographic and clinical data and participation consent.

2.6. Statistical Analysis

Results were presented as frequency (percent), median (range) and mean ± standard deviation (SD). Changes in the anti-spike IgG during the observed period were examined with a linear mixed effects modeling approach using R package lme4 version 1.1–26. The models fit was assess using Akaike’s information criterion (AIC). Results were graphically
presented using the R package ggplot2 version 3.3.2. Logistic regression was used as the method for analyzing binary outcomes (local and systemic AE) and potential predictors. Independent variables that were significant \((p < 0.1)\) in univariate logistic regression (ULRA) models were used as the independent variables in the multivariate logistic regression (MLRA) model. Hosmer and Lemeshow goodness-of-fit test was performed to determine how well the model fits the data. Multicollinearity was checked with Variance Inflation Factors (VIF). All \(p\)-values less than 0.05 were considered significant. Statistical data analysis was performed using IBM SPSS Statistics 22 (IBM Corporation, Armonk, NY, USA) and R-4.0.0 software (The R Foundation for Statistical Computing, Vienna, Austria).

2.7. Ethical Statement

The Ethics Committee of the Institute of Public Health of Serbia “Dr Milan Jovanovic Batut” approved the study (No 5139/1). Personal identifiers of study participants were coded, and patient records were anonymized and de-identified prior to analysis to maintain the confidentiality.

3. Results

3.1. Characteristics of the Study Participants

Out of 300 study participants, 185 (61.7\%) were female. The mean age for all participants was 52.7 (SD = 14.3). Pfizer-BioNTech was the most common COVID-19 vaccine used as a booster dose by 226 (75.3\%) participants, while 60 (20\%) and 14 (4.7\%) used Sinopharm BBIBP-CorV and Sputnik V, respectively. The homologous booster immunization was used in 127 (42.3\%) participants, while heterologous in 173 (57.7\%). Other characteristics are described in Table 1.

Table 1. Characteristics of the study participants \((n = 300)\).

| Characteristics                      | N   | %    |
|--------------------------------------|-----|------|
| Sex                                   |     |      |
| Male                                  | 115 | 38.3 |
| Female                                | 185 | 61.7 |
| Age category                          |     |      |
| 18–44                                 | 85  | 28.3 |
| 45–64                                 | 143 | 47.7 |
| 65+                                   | 72  | 24.0 |
| Education                             |     |      |
| High school or lower                  | 65  | 21.6 |
| University or higher                  | 235 | 78.3 |
| Employment                            |     |      |
| Employed                              | 221 | 73.7 |
| Retired                               | 63  | 21.0 |
| Student/Unemployed                    | 16  | 5.3  |
| Marital status                        |     |      |
| Married/cohabitation                  | 194 | 64.7 |
| Single                                | 106 | 35.3 |
| Residence                             |     |      |
| Urban/Suburb                          | 280 | 93.3 |
| Rural                                 | 20  | 6.7  |
| Currently smoking                     | 103 | 34.3 |
| Alcohol use                           | 70  | 23.4 |
| Concomitant diseases                  |     |      |
| Cardiac *                             | 109 | 36.3 |
| COPD ** and asthma                    | 22  | 7.3  |
| Diabetes ***                          | 40  | 13.3 |
| Thyroid                               | 35  | 11.7 |
| Malignant ****                        | 15  | 5.0  |
### Table 1. Cont.

| Characteristics                                      | N  | %  |
|-------------------------------------------------------|----|----|
| Previous COVID-19 infection                          | 19 | 6.3|
| Immunosuppressive treatment                          | 4  | 1.3|
| Allergy to food and drugs                            | 53 | 17.7|
| Type of booster dose of COVID-19 vaccine              |    |    |
| Sinopharm BBIBP-CorV                                  | 60 | 20.0|
| Pfizer-BioNTech                                      | 226| 75.3|
| Sputnik V                                            | 14 | 4.7|
| Homologous booster vaccination                       | 127| 42.3|
| IgG baseline titer                                   | 300| 100.0|
| Adverse events after first dose of COVID-19 vaccine   | 50 | 16.7|
| Adverse events after second dose of COVID-19 vaccine  | 51 | 17.0|
| Local adverse events 7 days after booster dose       | 214| 74.3|
| Systemic adverse events 7 days after booster dose     | 100| 34.7|

* Arterial hypertension, ischemic heart disease and cardiac insufficiency; ** chronic obstructive pulmonary disease; *** all types of diabetes; **** all localizations.

The most common vaccine combinations (primary vaccination series and booster doses) used are presented in Table 2.

Almost three-fourths of the participants, i.e., 214 (71.3%), reported local adverse events 7 days after the booster dose, while 100 (33.3%) of them reported systemic adverse events. Adverse events after the first dose of the COVID-19 vaccine were reported by 50 participants (16.7%) and by 51 (17.0%) participants after the second dose of the COVID-19 vaccine.

### Table 2. Distribution of applied vaccine combinations (primary vaccination series and booster doses, n = 300).

| Primary Vaccination Series and Booster Doses                        | N  | %  |
|---------------------------------------------------------------------|----|----|
| Sinopharm BBIBP-CorV + Sinopharm BBIBP-CorV                         | 59 | 19.7|
| Sinopharm BBIBP-CorV + Pfizer-BioNTech                             | 163| 54.3|
| Sinopharm BBIBP-CorV + Sputnik V                                   | 8  | 2.7|
| Pfizer-BioNTech + Pfizer-BioNTech                                  | 62 | 20.7|
| Pfizer-BioNTech + Sinopharm BBIBP-CorV                             | 1  | 0.3|
| Sputnik V + Sputnik V                                               | 6  | 2.0|
| Sputnik V + Pfizer-BioNTech                                        | 1  | 0.3|

#### 3.2. Analysis of Immunogenicity

The initial antibody titer after 6 months of the primary vaccination by all vaccines was 134.0 (range, 0–11,615.8). During the study period, there was a significant increase in anti-spike Ig G (B = 9757.4; p < 0.001, η² = 0.53) (Figure 1).

When applying the booster dose within the homologous regimen, the average increase in the anti-S-IgG was 8782.2 (after 7 days), while after 28 days it was 1213.9. Within the heterologous regimen, the average increase in the anti-S-IgG was 9179.5 (after 7 days), while after 28 days it was 16,728.1. Titers of anti-S-IgG in all applied vaccine combinations (primary vaccination series and booster dose) during the observed period are presented in Figure 2.

Based on the results presented in Figure 2, the Pfizer-BioNTech—Pfizer-BioNTech combination (primary vaccination series and booster dose) showed the biggest effect. In addition, the administration of the third dose of Pfizer-BioNTech in those who had previously received two doses of the Sinopharm vaccine as a primary series has also shown a substantial booster effect. On the other hand, other regimens (e.g., Sputnik–Sputnik) did not induce a significant response, although a modest rise in antibody levels has been observed in some individuals. Interestingly, a decrease in IgG values 28 days after the booster dose compared to 7 days after the booster dose of COVID-19 vaccines was observed in 17% (44/259) of participants who received the homologous booster of Pfizer-BioNTech. This decrease was associated with confirmed COVID-19 infections (OR = 5.64;...
95% CI = 1.16–19.67), homologous vaccines (OR = 4.89; 95% CI = 2.21–10.82) and adverse events after the second dose (OR = 2.53; 95% CI = 1.03–5.84). An analysis of the decrease in IgG values 28 days after the booster dose compared to 7 days after the booster dose of COVID-19 vaccines is presented in Table 3.

### Table 3. Univariate and multivariate analysis of the decrease in IgG values 28 days after the booster dose compared to 7 days after the booster dose of COVID-19 vaccines (n = 259).

| Characteristics                | Univariate | Multivariate |
|-------------------------------|------------|--------------|
|                               | OR (95% CI)| p-Value      | OR (95% CI) | p-Value |
| Sex (f vs. m)                 | 1.46 (0.72–2.96) | 0.292        | ref         | ref     |
| Age category                  |            |              |             |         |
| 18–44                         | 0.96 (0.94–0.98) | 0.001        |             |         |
| 45–64                         | 0.75 (0.37–1.52) | 0.423        | 0.91 (0.40–2.04) | 0.810 |
| 65+                           | 0.10 (0.02–0.43) | 0.002        | 0.20 (0.04–1.01) | 0.051 |
| Education (university vs. high)| 1.93 (0.77–4.83) | 0.161        |             |         |
| Employment                    |            |              |             |         |
| Employed                      | ref        |              |             |         |
| Retired                       | 0.12 (0.03–0.53) | 0.005        |             |         |
| Student/Unemployed            | -          |              |             | -       |
Table 3. Cont.

| Characteristics                          | Univariate OR (95% CI) | p-Value | Multivariate OR (95% CI) | p-Value |
|------------------------------------------|------------------------|---------|--------------------------|---------|
| Marital status (single vs. married)      | 0.89 (0.45–1.8)        | 0.754   |                          |         |
| Residence (urban vs. rural)              | 0.93 (0.26–3.4)        | 0.917   |                          |         |
| Currently smoking                        | 1.26 (0.64–2.48)       | 0.497   |                          |         |
| Alcohol use                              | 0.97 (0.48–1.96)       | 0.935   |                          |         |
| Concomitant diseases                     |                        |         |                          |         |
| Cardiac *                                | 0.27 (0.12–0.64)       | 0.003   | 0.38 (0.14–1.01)         | 0.053   |
| COPD ** and asthma                       | 0.23 (0.03–1.77)       | 0.158   |                          |         |
| Diabetes ***                             | 0.57 (0.13–2.54)       | 0.457   |                          |         |
| Thyroid                                  | 0.95 (0.34–2.63)       | 0.924   |                          |         |
| Malignant ****                           | 0.44 (0.06–3.5)        | 0.437   |                          |         |
| Previous COVID-19 infection              | 5.75 (1.9–17.37)       | 0.002   | 5.64 (1.16–19.67)        | 0.007   |
| Immunosuppressive treatment              | 1.67 (0.17–16.49)      | 0.659   |                          |         |
| Allergy to food and drugs                | 1.85 (0.87–3.94)       | 0.110   |                          |         |
| Type of booster dose of COVID-19 vaccine  |                        |         |                          |         |
| Pfizer-BioNTech ref                      | ref                    |         |                          |         |
| Sinopharm BBIBP-CorV                     | 0.59 (0.23–1.48)       | 0.256   |                          |         |
| Sputnik V                                | 2.00 (0.49–8.15)       |         |                          |         |
| Homologous booster COVID-19 vaccinations | 0.21 (0.1–0.43)        | <0.001  | 4.89 (2.21–10.82)        | <0.001  |
| Adverse events after first dose of COVID-19 vaccine | 3.21 (1.51–6.8) | 0.002 | | |
| Adverse events after second dose of COVID-19 vaccine | 3.34 (1.57–7.11) | 0.002 | 2.53 (1.03–5.84) | 0.043 |

* Arterial hypertension, ischemic heart disease and cardiac insufficiency; ** chronic obstructive pulmonary disease; *** all types of diabetes; **** all localizations.

Final multivariable model with IgG values as a dependent variable had marginal $R^2 = 0.52$ and conditional $R^2 = 0.55$. Sinopharm BBIBP-CorV booster dose ($B = -10,891.2$) and Sputnik V booster dose ($B = -9001.6$) in relation to the Pfizer-BioNTech booster dose as a reference category, 65 years and over ($B = -3449.1$) and currently smoking ($B = -2577.0$) were found to be independently associated with a lower level of anti-S-IgG, while adverse events after the second dose of the COVID-19 vaccine ($B = 3093.3$) were found to be independently associated with a higher level of anti-S-IgG (Table 4).

3.3. Analysis of Adverse Events after Booster Dose

All recorded adverse events were detected 7 days after the booster dose, while there were no local and systemic adverse events 28 days after the booster dose.

Local adverse events 7 days after the booster dose were reported in 214 (74.3%) of the study participants. The most common events were pain at the application site in 211 (70.3%), induration in 59 (19.6%), swelling in 55 (18.3%) and redness in 42 (14.0%). Female sex (OR = 2.79; 95%CI = 1.37–5.72) and homologous booster COVID-19 vaccinations (OR = 4.84; 95%CI = 1.98–11.78) were independently associated with more intense local adverse events 7 days after the booster dose, while older age, i.e., 65+ years (OR = 0.31; 95%CI = 0.11–0.87) and Sinopharm BBIBP-CorV booster dose (OR = 0.23; 95%CI = 0.07–0.67) in relation to the Pfizer-BioNTech booster dose as a reference category were found to be independently associated with less intense local adverse events 7 days after the booster dose (Table 5).

3.4. Systemic Adverse Events 7 Days after the Booster Dose

Systemic adverse events 7 days after the booster dose were reported in 100 (34.7%) participants. The most common events were fatigue experienced by 53 (17.7%), headaches in 30 (10.0%), myalgia by 29 (9.6%), shivering by 25 (8.3%), arthralgia by 25 (8.3%) and fever by 23 (7.6%).
Female sex (OR = 1.77; 95%CI = 1.01–3.12), previous COVID-19 infection (OR = 3.62; 95%CI = 1.13–11.63) and adverse events after the second dose of the COVID-19 vaccine (OR = 2.66; 95%CI = 1.33–5.32) were found to be independently associated with more intense systemic adverse events 7 days after the booster dose (Table 6).

Table 4. Univariate and multivariable linear mixed-effect regression models with IgG values as a dependent variable.

| Characteristics                      | Univariate |          | Multivariate |          |
|--------------------------------------|------------|----------|--------------|----------|
|                                      | B (95% CI) | p-Value  | B (95% CI)   | p-Value  |
| Sex (f vs. m)                        |            |          |              |          |
| Age category                         |            |          |              |          |
| 18–44                                | 570.7      | 0.538    |              |          |
| 45–64                                | −152.8     | <0.001   | −1583.0      | 0.057    |
| 65+                                  | −4381.7    | <0.001   | −3449.1      | 0.001    |
| Education (university vs. high)      |            |          |              |          |
| Employment                           |            |          |              |          |
| Employed                             |            |          |              |          |
| Retired                              | −3377.6    | 0.001    |              |          |
| Student/Unemployed                   | 1686.6     | 0.394    |              |          |
| Marital status (single vs. married)  | 1435.9     | 0.126    |              |          |
| Residence (urban vs. rural)          | 1424.9     | 0.431    |              |          |
| Currently smoking                    | −1890.7    | 0.057    | −2577.8      | <0.001   |
| Alcohol use                          | 1953.8     | 0.034    | 1221.0       | 0.084    |
| Concomitant diseases                 |            |          |              |          |
| Cardiac                              | −2265.6    | 0.015    | 377.0        | 0.642    |
| COPD ** and asthma                   | −2506.5    | 0.141    |              |          |
| Diabetes ***                         | −4100.0    | 0.015    | −1787.9      | 0.177    |
| Thyroid                              | −308.2     | 0.831    |              |          |
| Malignant ****                       | −3872.8    | 0.070    | −3378.0      | 0.039    |
| Previous COVID-19 infection          | 1841.0     | 0.333    |              |          |
| Immunosuppressive treatment          | −8626.3    | 0.025    | −1895.2      | 0.512    |
| Allergy to food and drugs            | −126.1     | 0.915    |              |          |
| Type of booster dose of COVID-19 vaccine |            |          |              |          |
| Pfizer-BioNTech                      | ref        |          | ref          |          |
| Sinopharm BBIBP-CorV                 | −11696.8   | <0.001   | −10891.2     | <0.001   |
| Sputnik V                            | −8156.4    | <0.001   | −9001.6      | <0.001   |
| Homologous booster COVID-19 vaccinations | 4338.8     | <0.001   | −1026.7      | 0.244    |
| Adverse events after first dose of COVID-19 vaccine | 628.9     | 0.603    |              |          |
| Adverse events after second dose of COVID-19 vaccine | 4472.8   | <0.001   | 3093.3       | 0.001    |

* Arterial hypertension, ischemic heart disease and cardiac insufficiency; ** chronic obstructive pulmonary disease; *** all types of diabetes; **** all localizations.

Table 5. Univariate and multivariate analysis of local adverse events 7 days after the booster dose of COVID-19 vaccines.

| Characteristics                      | Univariate |          | Multivariate |          |
|--------------------------------------|------------|----------|--------------|----------|
|                                      | OR (95% CI)| p-Value  | OR (95% CI)  | p-Value  |
| Sex (f vs. m)                        | 1.89 (1.11–3.23) | 0.020 | 2.79 (1.37–5.72) | 0.005 |
| Age category                         |            |          |              |          |
| 18–44                                | ref        |          | ref          |          |
| 45–64                                | 0.72 (0.36–1.46) | 0.362 | 0.80 (0.33–1.94) | 0.618 |
| 65+                                  | 0.28 (0.13–0.60) | 0.001 | 0.31 (0.11–0.87) | 0.026 |
| Education (university vs. high)      | 1.67 (0.91–3.08) | 0.098 | 1.21 (0.56–2.60) | 0.625 |
| Employment                           |            |          |              |          |
| Employed                             | ref        |          |              |          |
| Retired                              | 0.82 (0.25–2.66) | 0.739 |              |          |
| Student/Unemployed                   | 0.40 (0.22–0.74) | 0.003 |              |          |
### Table 5. Cont.

| Characteristics                             | Univariate |             | Multivariate |             |
|---------------------------------------------|------------|-------------|--------------|-------------|
| Marital status (single vs. married)         | 1.71 (0.96–3.06) | 0.071       | 1.14 (0.55–2.35) | 0.724       |
| Residence (urban vs. rural)                 | 1.04 (0.36–2.98) | 0.949       |              |             |
| Currently smoking                           | 1.06 (0.61–1.85) | 0.844       |              |             |
| Alcohol use                                 | 1.00 (0.57–1.78) | 0.988       |              |             |
| Concomitant diseases                        |            |             |              |             |
| Cardiac *                                   | 0.37 (0.22–0.64) | <0.001      | 0.49 (0.24–1.02) | 0.056       |
| COPD ** and asthma                          | 0.72 (0.28–1.85) | 0.496       |              |             |
| Diabetes ***                                 | 0.62 (0.26–1.53) | 0.302       |              |             |
| Thyroid                                     | 1.29 (0.50–2.94) | 0.675       |              |             |
| Malignant ****                              | 0.38 (0.13–1.18) | 0.095       | 0.37 (0.10–1.40) | 0.144       |
| Previous COVID-19 infection                 | 2.52 (0.56–11.36) | 0.229       |              |             |
| Immunosuppressive treatment                 | 0.34 (0.05–2.46) | 0.285       |              |             |
| Allergy to food and drugs                   | 1.01 (0.51–2.03) | 0.971       |              |             |
| Type of booster dose of COVID-19 vaccine    |            |             |              |             |
| Pfizer-BioNTech                             | ref        |             | ref          |             |
| Sinopharm BBIBP-CorV                        | 0.11 (0.06–0.22) | <0.001      | 0.23 (0.08–0.67) | 0.008       |
| Sputnik V                                   | 0.37 (0.11–1.30) | 0.120       | 0.56 (0.12–2.61) | 0.461       |
| Homologous booster COVID-19 vaccinations    | 6.68 (3.65–12.22) | <0.001      | 4.84 (1.98–11.78) | 0.001       |
| Adverse events after first dose of COVID-19 vaccine | 1.20 (0.58–2.49) | 0.630       |              |             |
| Adverse events after second dose of COVID-19 vaccine | 1.66 (0.76–3.61) | 0.201       |              |             |
| IgG baseline titer                          | 1.0001 (0.9999–1.0003) | 0.370       |              |             |
| IgG titer 7 days after booster dose         | 1.00004 (1.00001–1.00008) | 0.012       | 0.99999 (0.99995–1.00002) | 0.495       |

* Arterial hypertension, ischemic heart disease and cardiac insufficiency; ** chronic obstructive pulmonary disease; *** all types of diabetes; **** all localizations.

### Table 6. Univariate and multivariate analysis of systemic adverse events 7 days after the booster dose of COVID-19 vaccines.

| Characteristics                             | Univariate |             | Multivariate |             |
|---------------------------------------------|------------|-------------|--------------|-------------|
| Sex (f vs. m)                               | 1.76 (1.05–2.96) | 0.031       | 1.77 (1.01–3.12) | 0.046       |
| Age category                                |            |             |              |             |
| 18–44                                       | ref        |             |              |             |
| 45–64                                       | 0.66 (0.37–1.16) | 0.152       |              |             |
| 65+                                         | 0.67 (0.35–1.31) | 0.248       |              |             |
| Education (university vs. high)              | 1.15 (0.63–2.09) | 0.646       |              |             |
| Employment                                  |            |             |              |             |
| Employed                                    | ref        |             |              |             |
| Retired                                     | 0.83 (0.45–1.53) | 0.547       |              |             |
| Student/Unemployed                          | 1.88 (0.68–5.21) | 0.227       |              |             |
| Marital status (single vs. married)         | 1.16 (0.70–1.92) | 0.564       |              |             |
| Residence (urban vs. rural)                 | 3.01 (0.85–10.58) | 0.086       | 3.10 (0.83–11.56) | 0.092       |
| Currently smoking                           | 0.72 (0.43–1.21) | 0.220       |              |             |
| Alcohol use                                 | 1.00 (0.59–1.69) | 0.998       |              |             |
| Concomitant diseases                        |            |             |              |             |
| Cardiac *                                   | 0.85 (0.51–1.41) | 0.527       |              |             |
| COPD ** and asthma                          | 1.33 (0.55–3.23) | 0.527       |              |             |
| Diabetes ***                                 | 1.50 (0.63–3.54) | 0.360       |              |             |
| Thyroid                                     | 1.41 (0.66–3.01) | 0.374       |              |             |
| Malignant ****                              | 0.56 (0.15–2.05) | 0.373       |              |             |
| Previous COVID-19 infection                 | 3.37 (1.19–9.57) | 0.022       | 3.62 (1.13–11.63) | 0.031       |
| Immunosuppressive treatment                 | 0.34 (0.05–2.46) | 0.285       |              |             |
Table 6. Cont.

| Characteristics Univariate Multivariate |
|---------------------------------------|------------------------------------|
|                                       | OR (95% CI)     | p-Value | OR (95% CI)     | p-Value     |
| Allergy to food and drugs             | 1.40 (0.75–2.60) | 0.287    | ref             | ref         |
| Type of booster dose of COVID-19 vaccine |                   |         | ref             | ref         |
| Pfizer-BioNTech                      | 0.38 (0.18–0.78) | 0.008    | 0.59 (0.26–1.31) | 0.194        |
| Sinopharm BBIBP-CorV                  | 1.63 (0.51–5.21) | 0.413    | 2.34 (0.66–8.25) | 0.187        |
| Sputnik V                            | 1.29 (0.79–2.12) | 0.311    | 1.59 (0.84–2.98) | 0.152        |
| Homologous booster COVID-19 vaccinations |                   |         | ref             | ref         |
| Adverse events after first dose of COVID-19 vaccine | 3.43 (1.82–6.47) | <0.001  | 2.66 (1.33–5.32) | 0.006        |
| IgG baseline titer                    | 1.00006 (0.99990–1.00023) | 0.460    | 1.00002 (0.99999–1.00005) | 0.064        |
| IgG titer 7 days after booster dose   | 1.00004 (1.00002–1.00006) | <0.001  | 1.00002 (0.99999–1.00005) | 0.064        |

* Arterial hypertension, ischemic heart disease and cardiac insufficiency; ** chronic obstructive pulmonary disease; *** all types of diabetes; **** all localizations.

4. Discussion

The results of our study indicate that a heterologous vaccine regimen led to a significantly stronger booster of the humoral immune response 28 days after vaccine administration than the homologous one. Pfizer-BioNTech vaccine, as a booster, induced the strongest humoral immune response. Other predictors of a stronger humoral immune response were younger age, non-smoking status and the occurrence of adverse events after the second dose of the COVID-19 vaccine within the primary series of COVID-19 immunization. The diagnosis of malignant disease was a predictor of a weaker humoral immune response, while the presence of other chronic diseases was not found as a significant predictor. Receiving a booster dose of Pfizer-BioNTech, Sputnik V and Sinopharm BBIBP-CorV vaccines turned out to be safe and well tolerated. A low percentage of adverse events were reported up to the seventh day after receiving the booster dose of any of the given vaccines, while no adverse events were reported between the seventh and 28th day after the booster dose. Regardless of the type of adverse event (local or systemic), all reactions were mild to moderate in severity, without serious adverse events reported.

Other studies comparing homologous and heterologous vaccine regimens showed that heterologous vaccine administration boosted the humoral immune response significantly and strongly [15–18,26–31]. In line with our results, the advantage of a heterologous vaccine regimen with stronger humoral response is evident and can be explained by the administration of an mRNA-based vaccine as a second or booster dose [15–18,26–31]. Pfizer-BioNTech vaccine was shown to induce stronger humoral immune response (production of anti-receptor-binding domain (RBD) IgG, anti-spike protein IgG, IgA antibodies) in healthy individuals, as well as a two-fold higher T cell response [28]. Study by Petrovic et al. also demonstrated that the Pfizer-BioNTech vaccine induced higher antibody levels against S protein 28 days after vaccination with two doses, compared to Sputnik V and Sinopharm BBIBP-CorV [32]. Although less potent compared to other two vaccines, immune response after Sinopharm BBIBP-CorV was similar to the response measured in convalescents. Similarly, in a study from Mongolia, the strongest anti-spike antibody ACE2 blocking activity was noticed in the Pfizer-BioNTech vaccine, followed by AstraZeneca and Sputnik V vaccines, while the lowest levels were detected after the administration of Sinopharm BBIBP-CorV vaccine [26]. Taking all this into account, it is not surprising that a heterologous booster with Pfizer/BioNTech vaccine in our study induced stronger humoral response in subjects who received Sinopharm BBIBP-CorV vaccine as a primary series in comparison with the homologous booster regimen. In concordance with our findings, heterologous booster vaccination with the Pfizer/BioNTech vaccine in COVID-19-naïve individuals who had received two doses of the Sinopharm BBIBP-CorV vaccine was not only found to be
safe and well tolerated, but it was also significantly associated with higher anti-spike IgG geometric mean titers compared to that after homologous Pfizer/BioNTech immunization in COVID-19-naïve individuals [15]. Likewise, heterologous booster with Pfizer/BioNTech vaccine after Sinovac CoronaVac, another inactivated vaccine, boosted anti-spike IgG median titers by a factor of 46.6, compared to only 1.7 times increase after the homologous booster, although this was not observed for the humoral response against nucleocapsid (N) protein of SARS-CoV-2 [33].

Our study results as well as previous studies indicate that the Sinopharm BBIBP-CorV vaccine led to a slower and lower increase in anti-spike IgG 28 days after booster dose administration [15–18,23]. We examined the increase in titer of anti-spike IgG (anti-S-IgG), without testing the presence of antibodies to the SARS-CoV-2 N antigen produced only after receiving the Sinopharm BBIBP-CorV vaccine. A study by Dashdorj et al. found that individuals with higher anti-N antibodies, in addition to anti-spike antibody levels, have stronger ACE2-blocking antibody activity [26] in relation to those without anti-N antibodies. As the Sinopharm BBIBP-CorV vaccine induced T cell response targeting N and membrane (M) proteins similar to cell-mediated immune response in patients who recovered from COVID-19 [25], not the case with Pfizer-BioNTech vaccine, isolated the measurement of S protein-binding antibody titers after the COVID-19 vaccines is not sufficient to conclude the immune efficacy of Sinopharm BBIBP-CorV and other inactivated vaccines [28].

However, a correlation has been observed between higher antibody titers induced by different types of COVID-19 vaccines and a higher degree of protection against all known SARS-CoV-2 variants, despite various uncontrolled variables across the studies [29,30]. According to the latest results from the meta-analysis, the efficacy of vaccines against symptomatic infection caused by different variants of SARS-CoV-2 is reduced to below 50% within the first year after vaccination for some vaccines [34]. The initial levels of binding antibodies after two doses of inactivated vaccines begins to decline after 90 and 180 days, and after six months they are near or below the limit of seropositivity [30], which is similar to our results. It has been shown that a booster immunization enables greater neutralization of SARS-CoV-2 variants compared to primary vaccination [31]. The study by Zeng et al. demonstrated that administration of the third dose of inactivated vaccine after a longer time interval from the second dose (8 vs. 2 months) led to a stronger increase in the titer of neutralizing antibodies, which is approximately three to five times higher than titers observed 28 days after the second dose, while the reactogenicity of the third dose did not differ from the reactogenicity of the previous two doses [30]. In the present study, a booster dose was administered to participants after a minimum of 6 months, which could explain the strong response, especially after heterologous regimen. Regarding various factors that might affect immune response to vaccines, the association of older age, smoking and malignancy with lower humoral immune responses following the COVID-19 vaccine observed in our study is probably linked with different levels of immune suppression in those individuals, and such associations were also observed in previous studies [30–32]. Interestingly, we have observed a decline in IgG levels in the period between day 7 and day 28 post-vaccination in some participants in our study, mostly those who received Pfizer/BioNTech in homologous regimen. Although we are not able to explain this observation, it is worth mentioning that, in addition to the administration of homologous vaccines, the decrease in IgG values was also associated with confirmed COVID-19 infections and adverse events after the second dose.

Concerning the safety, the results of our study indicate that the frequency and severity of adverse events after receiving a booster dose of COVID-19 vaccine is neither higher nor different from the adverse events that occurred during the primary vaccination. In our cohort, female gender and the homologous booster dose of the COVID-19 vaccine were predictors of more intense local adverse events, and previous COVID-19 infection and adverse events after the second dose of the COVID-19 vaccine were predictors of more intense systemic adverse events notified within 7 days. Older age and the Sinopharm BBIBP-CorV vaccine used as a third dose were predictors of less intense local adverse
events within 7 days. Our results are consistent with the previous studies which examined the frequency of adverse reactions to combinations of different vaccine types. These studies have shown that the adverse reactions are more common after the Pfizer-BioNTech and AstraZeneca vaccine compared to inactivated vaccines and are generally mild to moderate in severity [15,18,34]. It has also been noticed that the frequency of adverse events after the vaccine against COVID-19 is higher among convalescents [34,35]. Additionally, the occurrence of side effects is more common in those who experienced side effects when receiving the previous dose of the COVID-19 vaccine [34,35].

In our study, adverse events observed after receiving any of the three COVID-19 vaccines (Pfizer/BioNTech, Sputnik V and Sinopharm BBIBP-CorV) were mild to moderate. In general, the incidence and severity of adverse events after inactivated vaccines are the lowest compared to those that follow the administration of mRNA or vector vaccines [34,35]. Pain at the site of vaccine injection and fatigue were the most reported local and systemic adverse events for all COVID-19 vaccines [17,18,31,34]. The fever is more often reported after receiving the Sputnik V vaccine [35]. In our study, it was noticed that the reactogenicity of the third dose did not differ significantly from the reactogenicity after the previous two doses, regardless of the type of vaccine applied, in accordance with the data from the literature [17,18,22,31].

Our study is the first one in Serbia which evaluated the immunogenicity and safety of administration of the booster dose and is one of the rare studies that assessed heterologous regimens that included the Pfizer/BioNTech, Sputnik V and Sinopharm BBIBP-CorV vaccines. However, this study has several limitations. It included a limited number of respondents due to the funding restraints. Therefore, we did not manage to recruit enough subjects to have equal distribution between the groups. Moreover, limited quantities of the Sputnik V vaccine were available for booster administration during the study implementation resulting in a small number of subjects receiving that vaccine as a booster, despite the interest among the participants. As a result, we cannot draw any firm conclusions about the effects of the Sputnik V vaccines used as a booster. Thus, a larger sample size is needed to explore these, and other factors associated with immune response and adverse events following immunization. Despite its limitations, our study provided baseline data about the safety and immunogenicity of mix and match strategies of the COVID-19 booster immunization in Serbia.

5. Conclusions

The application of the booster dose significantly increased antibody titers against spike protein, especially 28 days after the applied heterologous regimen. The observed increased immunogenicity of the booster dose was not accompanied by an increase in reactivity. Our study results also indicated the presence of low antibody titers recorded six months after the second dose of four COVID-19 vaccines administered.

Author Contributions: Concept and design M.S., M.M. (Marija Milic); statistical analysis Z.B.; interpretation of the data M.S., M.M. (Marija Milic), M.M. (Milos Markovic), I.K., Z.B., M.V., V.J.; drafting the manuscript M.S., M.M. (Marija Milic) and critical revision of the manuscript for important intellectual content M.S., M.M. (Marija Milic), M.M. (Milos Markovic), I.K., Z.B., M.V., D.K.T., V.S., D.P., S.J., V.J. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by NIS A.D. Novi Sad, grant number 5680/1.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Board of the Institute of Public Health of Serbia “Dr Milan Jovanovic Batut” (protocol code 5139/1 on 20 August 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The supporting data for the study findings are available from the corresponding author upon request.
Acknowledgments: The study team gratefully acknowledge the help of Marija Bulatovic and all those who supported our work, as well as doctors, nurses and technicians who made up the field study team, and whose exceptional commitment and cooperation was essential for conducting this research.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fiolet, T.; Kherabi, Y.; MacDonald, C.J.; Ghosn, J.; Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. *Clin. Microbiol. Infect.* 2022, 28, 202–221. [CrossRef] [PubMed]

2. Christie, A.; Henley, S.J.; Mattocks, L.; Fernando, R.; Lansky, A.; Ahmad, F.B.; Adjemianet, J.; Anderson, R.N.; Binder, A.M.; Carey, K. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine—United States, September 6, 2020–May 1, 2021. *MMWR Morb. Mortal. Wkly. Rep.* 2021, 70, 858–864. [CrossRef]

3. Mallapati, S. Vaccines are curbing COVID: Data from Israel show drop in infections. *Nature* 2021, 590, 197. [CrossRef] [PubMed]

4. Haas, E.J.; Angulo, F.J.; McLaughlin, J.M.; Anis, E.; Singer, S.R.; Khan, F.; Brooks, M.; Smaja, M.; Mircus, G.; Pan, K.; et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. *Lancet* 2021, 397, 1819–1829. [CrossRef]

5. Shirit, P.; Zuckerman, N.S.; Mor, O.; Gottesman, B.S.; Chowers, M. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. *Euro Surveill.* 2021, 26, 2100822. [CrossRef]

6. Favresse, J.; Bayart, J.L.; Mullier, F.; Elsen, M.; Eucher, C.; Van Eeckhoudt, S.; Roy, T.; Wiers, G.; Laurent, C.; Dogné, J.M.; et al. Antibody titres decline 3-month post-vaccination with BNT162b2. *Emerg. Microbes Infect.* 2021, 10, 1495–1498. [CrossRef]

7. Grant, R.; Charmet, T.; Schaeffer, L.; Galmiche, S.; Madec, Y.; Von Platen, C.; Chény, O.; Omar, F.; David, C.; Rogoff, A.; et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. *Lancet Reg. Health Eur.* 2021, 13, 100278. [CrossRef]

8. Steensels, D.; Pierlet, N.; Penders, J.; Mesotten, D.; Heylen, L. Comparison of SARS-CoV-2 Antibody Response Following Vaccination with BNT162b2 and mRNA-1273. *JAMA* 2021, 326, 1533–1535. [CrossRef]

9. Mahase, E. COVID-19: Third vaccine dose boosts immune response but may not be needed, say researchers. *BMJ* 2021, 373, n1659. [CrossRef]

10. Sesa, G.; Siepman, I.; Czabanowska, K.; Martin-Moreno, J.M.; Green, M.; Reid, J.; Middletonet, J. The Importance of Health Communication during Emergencies. The Mix-and-Match Question. 2021. Available online: https://www.aspher.org/download/796/aspher_dosemixing-23072021.pdf (accessed on 5 March 2022).

11. Rashedi, R.; Samieefar, N.; Masoumi, N.; Mohseni, S.; Rezaei, N. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. *J. Med. Virol.* 2022, 94, 1294–1299. [CrossRef]

12. Lijeskić, O.; Klun, I.; Djaković, M.S.; Gligorić, N.; Stajner, T.; Srbjanović, J.; Djurković-Djaković, O. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report. *Vaccines* 2021, 9, 1031. [CrossRef] [PubMed]

13. AliQahtani, M.; Bhattacharyya, S.; Alawadi, A.; Al Mahmeed, H.; Al Sayed, J.; Justman, J.; El-Sadr, W.M.; Hidary, J.; Mukherjee, S. Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with various COVID-19 vaccines and the emergence of variants in the Kingdom of Bahrain. *Res. Sq.* 2021. [CrossRef]

14. Reuters. Serbia Authorises Third Shot of COVID-19 Vaccine, Minister Says. 15 August 2021. Available online: https://www.reuters.com/world/europe/serbia-authorises-third-shot-covid-19-vaccine-minister-says-2021-08-15 (accessed on 6 March 2022).

15. Moghnieh, R.; Mekdashi, R.; El-Hassan, S.; Abdallah, D.; Jisr, T.; Bader, M.; Jizi, I.; Sayegh, M.H.; Bizri, A.R. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon. *Vaccine* 2021, 39, 6713–6719. [CrossRef]

16. Saiag, E.; Goldshmidt, H.; Sprecher, E.; Ben-Ami, R.; Bomze, D. Immunogenicity of a BNT162b2 vaccine booster in health-care workers. *Lancet Microbe* 2021, 2, e650. [CrossRef]

17. Munro, A.P.S.; Janani, L.; Cornelius, V.; Aley, P.K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; Dodd, K.; et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021, 398, 2258–2276. [CrossRef]

18. Angkasekwinai, N.; Niyyomnaitham, S.; Sewatanon, J.; Phumiamorn, S.; Sukapirom, K.; Senawong, S.; Mahasirimongkol, S.; Quan Toh, Z.; Umrod, P.; Sompon, T.; et al. The immunogenicity and safety of different COVID19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series. *medRxiv* 2021, preprint.

19. Kerekes, S.; Ji, M.; Shih, S.F.; Chang, H.Y.; Harapan, H.; Rajamootry, Y.; Singh, A.; Kanwar, S.; Wagner, A.L. Differential Effect of Vaccine Effectiveness and Safety on COVID-19 Vaccine Acceptance across Socioeconomic Groups in an International Sample. *Vaccines* 2021, 9, 1010. [CrossRef]
20. Wagner, A.L.; Sheinfeld Gorin, S.; Boulton, M.L.; Glover, B.A.; Morenoff, J.D. Effect of vaccine effectiveness and safety on COVID-19 vaccine acceptance in Detroit, Michigan, July 2020. *Hum. Vaccine Immunother.* 2021, 17, 2940–2945. [CrossRef]

21. Kaplan, R.M.; Milstein, A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2021726118. [CrossRef]

22. Barda, N.; Dagan, N.; Cohen, C.; Hermán, M.A.; Lipsitch, M.; Kohane, I.S.; Reis, B.Y.; Balicer, R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. *Lancet* 2021, 398, 2093–2100. [CrossRef]

23. G-Power. Available online: https://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower (accessed on 5 March 2022).

24. Institute of Public Health of Serbia “Dr Milan Jovanović Batut”. National Methodological Guidelines for COVID-19 Vaccination. Available online: https://www.batut.org.rs/download/smuZaVanrednuPreporucenuImunizacijuProtivCOVID19.pdf (accessed on 5 March 2022).

25. Center for Disease Control and Prevention. Understanding Adverse Events and Side Effects. Available online: https://www.cdc.gov/vaccinesafety/ensuringsafety/sideeffects/index.html (accessed on 5 March 2022).

26. Dashdorj, N.J.; Wirz, O.F.; Röltgen, K.; Haraguchi, E.; Buzzanco AS 3rd, Sibai, M.; Wang, H.; Miller, J.A.; Solis, D.; Sahoo, M.K.; Arunachalam, P.S.; et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. *Cell Host Microbe* 2021, 29, 1738–1743.e4. [CrossRef] [PubMed]

27. Hillus, D.; Schwarz, T.; Tober-Lau, P.; Vanshylla, K.; Hastor, H.; Thibeault, C.; Jentzsch, S.; Helbig, E.T.; Lippert, L.J.; Tschéak, P.; et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study. *Lancet Respir. Med.* 2021, 9, 1255–1265. [CrossRef]

28. Pélyi-Nagy, I.; Matula, Z.; Gönézi, M.; Tasnády, S.; Bekő, G.; Réti, M.; Ajzner, É.; Uher, F. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. *Geroscience* 2021, 43, 2321–2331. [CrossRef] [PubMed]

29. Barros-Martins, J.; Hammerschmidt, S.I.; Coßmann, A.; Odak, I.; Stankov, M.V.; Morillas Ramos, G.; Dopfer-Jablonska, A.; Heidemann, A.; Ritter, C.; Friedrichsen, M.; et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat. Med.* 2021, 27, 1525–1529. [CrossRef] [PubMed]

30. Zeng, G.; Wu, Q.; Pan, H.; Li, M.; Yang, J.; Wang, L.; Wu, Z.; Jiang, D.; Deng, X.; Chu, K.; et al. Immunogenicity, and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect. Dis.* 2021. [CrossRef]

31. Atmar, R.L.; Lyke, K.E.; Deming, M.E.; Jackson, L.A.; Branche, A.R.; El Sahly, H.M.; Rostad, C.A.; Martin, J.M.; Johnston, C.; Rupp, R.E.; et al. Homologous and Heterologous COVID-19 Booster Vaccinations. *N. Engl. J. Med.* 2022, NEJMoa2116414. [CrossRef]

32. Petrović, V.; Vuković, V.; Padić, A.; Marković, M.; Ristić, M. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. *PLoS ONE* 2022, 17, e0263468. [CrossRef]

33. Keskin, A.U.; Boluksu, S.; Ciragil, P.; Topkaya, A.E. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. *J. Med. Virol.* 2022, 94, 39–41. [CrossRef]

34. Pormohammad, A.; Zarei, M.; Ghorbani, S.; Mohammadi, M.; Razzazadeh, M.H.; Turner, D.L.; Turner, R.J. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Vaccines* 2021, 9, 467. [CrossRef]

35. Cheng, H.; Peng, Z.; Luo, W.; Si, S.; Mo, M.; Zhou, H.; Xin, X.; Liu, H.; Yu, Y. Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. *Vaccines* 2021, 9, 582. [CrossRef]